| T1052 | Proglumide | Proglumide is a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. Proglumide is a drug that exerts an inhibitory effect on gastric secretion and reduces gas |
| T11868 | Lorglumide sodium salt | Lorglumide sodium salt is a potent cholecystokinin (CCK) receptor antagonist. |
| T15759 | Lintitript | Lintitript is an orally active, competitive, and non-peptide cholecystokinin (CCK1) receptor antagonist (EC50: 6 nM; Ki: 0.2 nM). Lintitript shows > 33-fold selectivity more selec |
| T2312 | Loxiglumide | Loxiglumide is a cholecystokinin (CCK-1) receptor antagonist. |
| T3352 | XL413 | XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. XL-413 binds to and inhibits the activity of CDC7, wh |
| T6206 | PHA767491 | PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively. |
| T6735 | XL413 hydrochloride | XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. CDC7 kinase inhibitor BMS-863233 binds to and inhibit |
| T6940 | PHA767491 HCl | PHA-767491 is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM). It has ~20-fold selectivity against GSK3-β and CDK1/2, 50-fold selectivity against CDK5 and M |
| TQ0062 | Nastorazepide | Nastorazepide (Z-360) is a selective, orally available antagonist of gastrin/cholecystokinin 2 (CCK-2) receptor with potential antineoplastic activity. |
